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The Dominant-Lethal Test: Potential
Limitations and Statistical Considerations
for Safety Evaluation
by Sidney Green* and Janet A. Springert
Introduction investigations male rats are dosed singly
In June of 1971, two independent labora- (acute) and mated with groups of untreated
tories under contract with the Food and virgin females over sequential weekly inter-
Drug Administration were given the re- vals, usually for 8 weeks. In the subacute test
sponsibility of determining the potential the male rats are dosed on five consecutive
** 11- * St - ~~days and then mated. Ten males are gener- mutagenicity of 24 food additives generally
g ally used for each dose level and mated with
two virgin females each week. The following was to be accomplished by an examination l. - three parameters are counted for each fe- of these compounds by the host-mediated.
y in male: total corpora lutea, total implants, assay, in vivo cytogenetic assay, and the'
dominant-lethal test. ..and dead implants. Corpora lutea minus
. total implants gives a direct measure of the This communication will focus upon one : -preimplant losses for each female. of the three assays, namely, the dominant-
lethal assay. We wish to point up problem is
encountered in attempting to use the results
to evaluate safety and how these may limit
the extent to which the assay may be em-
ployed in safety evaluations. It is not in-
tended to present the results of the tests of
the 24 GRAS compounds by the dominant-
lethal assay.
The nature of these problems is twofold:
first, the biology of the system, and second,
the statistical considerations. The detailed
methodology involved for the dominant-leth-
al test employing mice and rats has been
described previously (2, 3). In the present
*Division of Toxicology, Food and Drug Adminis-
tration, Department of Health, Education, and Wel-
fare, Washington, D. C. 20204.
tDivision of Mathematics, Food and Drug Ad-
ministration, Department of Health, Education,
and Welfare, Washington D. C. 20204.
Evaluation of Untreated Controls
A large body of control data was avail-
able from the three laboratories including
the FDA laboratory. Over 260 weekly means
were tabulated for control rats from over 30
experiments. These control data were exam-
ined for consistency and trends.
- There were no significant differences
(p> 0.05) between the acute and subacute
studies in the control values of corpora lutea,
total implantations, dead implantations, or
preimplantation losses. Within a few ex-
periments, the route of administration had
an effect on total implantations for control
rats; however, this effect was not consistent
from experiment to experiment. In two stud-
-ies- with Holtzman rats, the mean control
value over 10 weeks was lower by one im-
December 1973 371 I 1 12 13 14 15 16
MEAN CORPORA LUTEA PER FEMALE
FIGURE 1. Distribution of weekly mean corpora lutea
per pregnant female: (A) laboratory 1; (B)
laboratory 2; (C) laboratory 3.
plantation per female when the control
solvent was given intraperitoneally than
when it was given by intubation. However,
the mean number of dead implantations per
female over all weeks was almost identical
for the two different routes of administra-
tion. Control data were therefore pooled for
the different routes of administration and
for acute and subacute studies.
Figure 1 shows the distribution of con-
trol means for the entire set of control data
within each laboratory for corpora lutea per
pregnant female, when the mean is the
average for one week, one experiment. Fig-
ure 2 shows the distribution for mean total
implantations within each laboratory. These
two parameters are normally distributed for
each female. The distribution of control
means of these two parameters is fairly
comparable for the three laboratories.
Figures 3 and 4 show the distribution of
weekly means for preimplantation losses
and dead implantations. Late deaths and
MEAN IMPLANTS PER PREGNANT FEMALE
FIGURE 2. Distribution of weekly mean implants per
pregnant female: (A) laboratory 1; (B) labora-
tory 2; (C) laboratory 3.
early deaths were measured for each animal.
However, since late deaths were extremely
rare, they were included with early deaths
and analyzed as dead implantations. Al-
though these two parameters were extremely
skewed in individual females, the means are
more normally distributed, as would be ex-
pected.
The mean control v-alues for both preim-
plantation losses and dead implantations are
higher for laboratory 2 than laboratory 3.
This indicates that controls must be run for
each laboratory, and although negative con-
trol data from one laboratory certainly give
an indication of what would be expected in
controls from another laboratory, testing of
compound effects would necessitate controls
within the laboratory doing the test.
In FDA's contracting work, a file of his-
torical control data is being built within
each contracting laboratory. Each set of new
controls is compared against the historical
controls for each week. If the new data are
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MEAN PREIMPLANT LOSSES PER PREGNANT FEMALE
FIGUIRE 3. Distribution of weekly mean preimplanta-
tion losses per pregnant female: (A) laboratory 1;
(B) laboratory 2; (C) laboratory 3.
not significantly different (p>0.05) from
the historical data, the new group is added
to the historical file. Each test compound is
compared to both the historical control and
the concurrent control. Significance of re-
sults with concurrent controls is interpreted
in light of the significance against historical
controls. However, the importance of con-
current controls cannot be overemphasized.
The Necessity For Repeats
In evaluating the results of dominant-
lethal testing, one of the areas of major con-
cern is the necessity for replication of tests.
Of the 22 GRAS compounds tested and
evaluated by contract laboratories to date,
only one is a strong presumptive positive
for preimplantation and postimplantation
loss. The results from eight compounds clear-
ly showed no dominant-lethality and could
therefore be regarded as conclusively nega-
tive.
The compounds which are considered ques-
tionable positives are listed in Table 1. These
questionable positives are not based simply
upon one dose level in one week showing
a significant effect, but rather upon an analy-
sis of variance over all weeks in some in-
stances and in other instances upon cluster-
ing of significant effects around one or two
weeks.
Thirteen compounds generated enough of
a response in one of the parameters meas-
ured to preclude a statement regarding
their safety as determined by the dominant-
lethal assay. Five compounds from lab-
oratory 2 were in this questionable category
and eight from laboratory 3. In both labora-
tories, the parameter with the greatest num-
ber of questionables was preimplanation loss
as a result of subacute administration. Sec-
ond in the order of frequency was the meas-
ure of postimplantation loss from subacute
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MEAN DEAD IMPLANTS PER PREGNANT FEMALE
FIGURE 4. Distribution of weekly mean dead implants
per pregnant female: (A) laboratory 1; (B)
laboratory 2; (C) laboratory 3.
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39Table 1. Number of GRAS compounds considered "questionable positive" and the
response elicited by each.
No. of GRAS GRAS
compounds compounds producing compounds producing
examined preimplantation loss postimplantation loss
Acute Subacute Acute Subacute
Laboratory 2 14 A,B,M C M,N
A thru N
Laboratory 3 8
0 thru V P,S,V 0,R,S,T,U P,Q,V Q,S,U,V
Letters indicate codes for GRAS compounds: A, FD&C Red No. 2; B, calcium carrageenan; C, gum
arabic; M, sodium metabisulfite; N, ional C.P.; 0, ammoniated glycerrhizin; P, ammonium saccharin; Q,
sodium carrageenan; R, calcium saccharin; S, potassium nitrate; T, potassium nitrite; U, sodium sac-
charin; V, sodium bisulfite.
treatment. However, the degree of signifi-
cance for preimplantation loss in most cases
was at the 0.01 level, whereas that of the
postimplantation loss was at the 0.05.
The investigator faced with making a
safety evaluation based upon the configura-
tion of the data has an immediate problem.
Due to the lack of consistency, there is a
need to repeat the studies in question. Ap-
proximately 50%b of the compounds tested
fell into the questionable category. If one
were to extrapolate to the total number of
compounds on the GRAS list currently sche-
duled to be tested for mutagenicity this
would represent approximately 45 com-
pounds.
Clearly, there is a need for a more re-
fined method of looking at dominant-lethal
effects; one which would not give an inordi-
nate number of false negatives or false posi-
tives.
From experience, it appears that few, if
any, compounds exert their effect in one
week only. Therefore, an analysis of vari-
ance over specific spermatogenic stages may
be the better method, coupled with weekly
analysis. For example in the rat, the first 2
weeks could be analyzed, the following 3,
the next 3 and the final 2. These reflect
periods in which effects on spermatozoa.
spermatids, spermatocytes, and spermato-
gonia, respectively, are manifest (4). This
method of analysis could not serve as an
adequate protocol for chronic testing be-
cause the extended treatment would obliter-
ate the assessment of stage sensitivity. There
would be no rationale for the weekly group-
ing. If the analysis of variance for specific
stages is the best method of determining
dominant lethality and of limiting the num-
ber of questionables, while chronic exposure
of animals is the best dosage regimen for
safety evaluation, (that is, for substances to
which we are chronically exposed), a con-
flict arises, and the analysis of variance test
cannot be employed in what is considered
the most statistically powerful and biologi-
cally meaningful fashion.
Use of the Analysis of Variance
In an attempt to decrease the incidence of
spurious effects at one week only, an analy-
sis of variance was accomplished across all
doses and all weeks on 23 compounds. The
model used in the analysis was
Xijkl = A + al + Pi(k)+ ± jJ + X,j
dose male (dose) weeks weeks X dose
+ WJ(k) + ei(ijk)
male X weeks (dose) female (dose X weeks X male)
Doses and weeks were considered fixed
effects; males were considered random ef-
fects.
The data for corpora lutea and total im-
plantations per pregnancy are normally dis-
tributed and were not transformed. Preim-
plantation and post-implantation losses per
pregnancy were essentially Poisson-
Environmental Health Perspectives 40distributed and were transformed by using
the Freeman-Tukey square-root transforma-
tion.
The results of the analysis indicate that
the week effect is the greatest source of
variation within an experiment. This was
true of all four parameters. The week
variation was greater for preimplantation
losses than for dead implantations, but was
significant for both. The need for analysis of
the data on an individual week basis, or at
least on the separate stages of spermato-
genesis, is indicated.
The analysis showed that the variability
between males is accounted for by the vari-
ability between females mated to the same
male. The between male component of vari-
ance is essentially zero, indicating that analy-
sis on a per female basis is appropriate,
even though the males are the treated ex-
perimental unit.
The analysis of variance indicated that
the group by week interaction was gener-
ally not significant for any parameters, that
is, the trend across dose levels was not
significantly different from week to week,
although it was variable and there were in-
consistencies.
The analysis of variance was also carried
out for each stage of spermatogenesis: weeks
1-2; weeks 3, 4, and 5; weeks 6, 7, and 8.
These analyses indicated significant variabil-
ity between weeks, even within one stage of
spermatogenesis. For at least two compounds
there was a significant dose-related effect in
one stage of spermatogenesis with no cor-
responding effect in another stage. This
further illustrates the need for analysis at
each stage of spermatogenesis. It appears
that a dominant-lethal effect at only one
stage of spermatogenesis cannot be counted
as a negative effect.
The mean residual error variance for an
experiment, that is, between the two fe-
males mated to the same male, was 1.0 for
dead implants with a range of 0.34 4.78.
These figures are based on pooling the data
for all experiments over all dose levels, all
weeks. The error variance for individual
weeks had a considerably greater range. For
preimplantation losses the mean residual er-
ror variance was 1.62 with a range of 0.36-
5.85. The increase in the mean preimplanta-
tion loss for treatment over control that
could be detected as significant at the 5%o
level (assuming 20 females per-dose) based
on the mean residual variance is 0.9. Across
all weeks, the increase in mean-preimplanta-
tion losses per female that could be detected
as significant (based on 160 females per
dose) is 0.3. For dead implants, these dif-
ferences would be 0.7 for an individual week,
and 0.2 across all weeks. As was pointed
out before, these figures would vary slightly
for different laboratories. The strain of rat
would also affect the error variance.
Correlations between Parameters.
Correlations between corpora .lutea and
preimplantation losses per female, preim-
plantation loss and dead implantations, and
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FIGURE 5. Distribution of correlations between the
parameters for control rats: (A) dead implanta-
tions with total implantations; (B) preimplanta-
tion loss with dead -implantations; -(C) preim-
plantation loss with corpora lutea.
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FIGURE 6. Distribution of correlation between
parameters for rats (treatment and positive
control): (A) dead implantation with total
implantations; (B) dead implantations with pre-
implantation losses; (C) preimplantation loss with
corpora lutea.
dead implantations and total implantations
per female were calculated for each week of
each experiment. A frequency distribution
of the correlations is shown in Figures 5 and
6 for rats and Figure 7 for mice. There is a
tendency for dead implantations to be posi-
tively correlated with total implantations,
although this correlation is not a strong one.
This may indicate that the commonly used
mutagenic index defined as dead implanta-
tions/total implantations is a valid index to
use in evaluating the dominant-lethal test.
This positive correlation would indicate that
the dead implantations per female should be
adjusted by the total implantations for that
female, which is essentially what the use of
the index does. These observations are con-
trary to what has been reported in the work
of Epstein et al. (2), who reported no
correlation between dead implantations and
total implantations when using weekly
means. The statistician may object to use
of indexes on purely aesthetic grounds be-
cause of the problems of variance estimates
for a ratio, but this does not mean that
the index may not be the best interpreta-
tion of the data. In any case, the FDA has
been analyzing all data on dead implanta-
tions on a dead implantations per female
basis and on a dead implantations/total im-
plantations per female basis, and the in-
ferences as to significance are comparable.
The preimplantation losses are strongly
correlated with corpora lutea count. This
would indicate the need for preimplanta-
tion losses to be adjusted by corpora lutea
count for each female.
Preimplantation losses and dead implanta-
tions appear not to be correlated. The higher
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FIGURE 7. Distribution of correlation between dead
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(A) control mice; (B) treatment levels and posi-
tive control.
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FIGURE 8. Trends in weekly parameter means.
correlations are positive; however, no def-
inite trend is evident. One may expect that
the same animal which shows preimplanta-
tion losses also shows dead implantations.
With a strong positive compound, however,
if a heavy preimplantation loss is shown in
one female, dead implantations may be few,
since there are fewer implantations to be
affected.
There was considerable week to week vari-
ability in all parameters within an experi-
ment. No consistent trends were apparent,
however, from week to week. The control
data were combined across all experiments
by week to determine if a trend emerged.
Figure 8 shows the weekly trends for each
parameter. The mean dead implantations
per pregnancy shows an interesting cyclic
trend. The variability in each point on the
chart is the variability between experiments.
This variability is much greater than the
overall elevation in weekly means, thus this
trend is probably not significant.
The mean preimplantation losses show no
consistent trend across weeks (Fig. 8). The
high value for week 1 may indicate de-
creased viability of the sperm in the male
which is being mated for the first time.
The mean total implantations and the mean
corpora lutea show no consistent trends with
weeks of mating. Although these data might
seem to suggest pooling negative controls
over weeks and comparing each dose level
to the pooled data, this procedure may not
be valid, as will be shown later in this com-
munication.
The Preimplantation Problem
The propensity of the test for showing
significant preimplantation loss, especially
in the earlier weeks, presents another prob-
lem. Table 2 shows the number of ques-
tionable compounds exhibiting preimplanta-
tion loss in the first two weeks. Four of the
eight compounds shown in this table (sodium
metabisulfite, ammonium saccharin, potas-
sium nitrite, sodium saccharin) did show a
correlation to postimplantation loss at the
same week or the week immediately follow-
ing. This leads us into a comparison of the
variability in the preimplantation and the
postimplantation parameters among experi-
ments.
The mean resorption rate is consistent
from week to week and from experiment to
experiment as shown in Figure 3. The pre-
implantation losses (Fig. 4) are more vari-
able in the controls, particularly from week
to week in the same experiment. The latter
observation may be due to dirnculties in read-
ing corpora lutea. For this reason, the re-
sorptions are a better measure of dominant
lethal effects. This observation has been re-
ported before by Epstein et al. (2). How-
ever, it appears that with many compounds,
as shown in Table 2, an effect is seen in pre-
implantation losses with no corresponding
effect on dead implantations. Preimplanta-
tion losses may be a more sensitive indicator
of toxic activity than dead implants, though
more difficult to measure.
Investigators familiar with dominant leth-
al testing acknowledge that preimplanta-
December 1973 43Table 2. Number of questionable GRAS compounds
showing preimplantation loss in the first two weeks
GRAS compounds showing preimplantation loss
Acute Subacute
P,R O,R,T,U
A,B,M
a Letters indicate codes for. GRAS compounds: A,
FD&C Red No. 2; B, calcium carrageenan; C, gum
arabic; M, sodium metabisulfite; N, ional C.P.; 0,
ammoniated glycerrhizin; P, ammonium saccharin;
Q, sodium carrageenan; R, calcium saccharin; S,
potassium nitrate; T, potassium nitrite; U, sodium
saccharin; V, sodium bisulfite.
tion loss in earlier weeks when not coupled
with postimplantation loss in later weeks or
at lower dosage levels is meaningless, be-
cause it cannot be correlated with the general
basis of the dominarnt-lethal test; that is, it
cannot be correlated with postimplantation
losses. This philosophy is manageable for
persons interested only in precise genomal
effects, but what. is'-the' proper posture for
those individuals concerned with safety
evaluation?
When preimplantation loss occurs without
concomitant- postimpl-antation loss, certain
questions immediately -arise, such as: What
are the responsible -events? Do they involve
true dominant-lethality, or simply aspermia,
or oligospermia?- The- etiology of the preim-
plantation loss must-be' investigated, before
any decision regarding safety evaluation can
be made. The experimental procedures neces-
sary to obtain the answers are very tedious,
therefore prolonging the decision-making
process.
One possible approach to the preimplanta-
tion loss problem is to premate males which
should eliminate the questionable results in
the first week. There-'is- some evidence from
statistical evaluation of -males and females in
control groups that this problem is due to
the males.
Certain results of the analysis of variance
may bear on the above problem. For three
compounds; there wa-s -.a significant differ-
ence-between males-at-weeks 1 and 2 only, in
at lea-st one,parameter. The males not having
been mated previous to the study, react dif-
ferently for weeks 1 and 2, particularly week
1, than for the remaining weeks of mating.
This may seem to indicate the desirability
of premating. However, the significant effects
of the test compound seem to be more pro-
nounced in the first two weeks of mating. The
virgin male may be more susceptible to the
dominant-lethal effect, and premating would
mask the effect.
One larger question arises, however, and
that is why should virgin males be more
sensitive to causing preimplantation losses
than experienced breeders. One should there-
fore be cautious of preimplantation losses in
the first week when analysis shows this to
be due to male variability. At the same time
we cannot totally discount effects in treated
groups in the first week, which are highly
significant.
The Dose-Response Problem
Another area of concern has to do with
the fact that most of the positive effects
seem to occur at the lowest dosage level
tested. It is generally accepted among phar-
macologists that a compound should exhibit
a dose response; that is, there is a direct
relationship between the dose of a com-
pound and the magnitude or intensity of the
response it elicits. This point is especially
critical for safety evaluation, as one would
expect.
With approximately half of the compounds
studied, the most important parameters were
not dose-related. When these differences are
significant as tested by analysis of variance,
they cannot be attributed to individual
males or females, because variability be-
tween females within a group is taken into
account in the analysis of variance. The
significance of effects at low or intermedi-
ate dose levels compared to controls seems
too pronounced in some cases to be ignored.
To illustrate this point, the results ob-
tained for potassium nitrite in the subacute
study for preimplantation losses are shown
in Table 3. The results at the low dose level
are too far above the ranges of all negative
control data to be ignored. The experience
with dominant-lethal data is not enough to
Environmental Health Perspectives 44Table 3. Mean preimplantation losses for the
Subacute study on potassium nitrite of
laboratory 3.
Mean preimplantation losses
Negative Low Intermediate High
Week control dose dose dose
1 and 2 0.53 2.47 1.39 2.12
3, 4, and 5 1.25 2.59 2.24 1.69
6 and 7 0.96 2.29 1.55 1.52
say what models may be applicable, and
models assuming a (linear) dose-related
response may not be valid (for many of
the GRAS compounds) in the dose ranges
studied. The classical compounds used in
dominant-lethal studies, such as TEM, TE-
PA, and EMS, all have well-known mechan-
isms of action which demonstrate definite
dose-response relationships (3, 5). Com-
pounds having dissimilar mechanisms of
action from the alkylating agents may not
exhibit as definitive a dose response.
When a compound does not exhibit a di-
rect dose-response relationship, it is generally
assumed the compound is not acting phar-
macologically. In other words, there are
other unknown factors contributing to the
response. We must seriously consider the pos-
sibility of hormonal effects or of abnormal
or disturbed metabolism and pharmacokine-
tics at the maximum tolerated dosage (MTD)
as a possible source of the problem. If this
is the case, then testing at lower dosage
levels is essential. Therefore, we must modify
our protocols to either include additional
dosages, or, on the basis of experience, choose
levels below the LD5 as the highest level
to be tested.
It may be, however, that the MTD is not
causing the above problem. Whatever the
cause, this is an area of major concern, for
without a dose-response effect it is not cer-
tain whether the compound is responsible
for the effect. At some later point in time
we may question the relevance of a dose
response, as now with carcinogens, but the
present state of the art dictates that we re-
late these effects to pharmacological and
toxicological principles.
Extrapolation of results is not discussed
here. Sufficient models have not been devel-
oped, and all relevant problems have not
been explored for valid extrapolation of data
to lower dose levels. The only investigation
in which a model was used employed the
probit model for the proportion of females
with one or more dead implants in a study
on TEPA and METEPA (5). The authors
stated that their model was not a sufficient
fit and there were significant departures
from the assumed model.
Expansiveness of Dominant-Lethal Data
as a Problem
The inordinate amount of time required to
examine adequately results from dominant-
lethal testing is another area of concern. Any
system promulgated for safety evaluation
should have as one of its primary features a
minimum amount of information necessary
to accomplish its purpose. We realize that a
careful and sometimes laborious examination
of data must take place in order to draw
meaningful conclusions. There should be,
however, a development of better methods of
evaluation to reduce the expansiveness of
data now required for dominant-lethal test-
ing.
In addition to the above consideration,
departures from adequate performance on
the part of technical personnel increase the
probability of obtaining spurious results.
Table 4 is an illustration of possible tech-
nical difficulties which influence the pattern
of control results. Calcium saccharin shows
negative control preimplantation losses
which are much smaller than historical con-
trols. We might, therefore, expect signific-
ance for the test compound which is en-
tirely due to the low negative control. How-
ever, here is a case where the preimplanta-
tion losses for every level of the test com-
pound and even the positive control are
significantly lower than the historical nega-
tive control values. Similar results were ob-
tained for the same compound on the sub-
acute study. Therefore, significant differ-
ences between concurrent-controls and.-test
groups cannot be completely discounted-be-
December 1973 45Table 4. Mean preimplantation losses for the acute study on calcium saccharin of laboratory 3.
Mean preimplantation losses
Historical Negative Low Intermediate High Positive
Week control control dose dose dose control
4 0.6 0.1 0.3 0.3 0.1 0.8
5 0.6 0.08 0.1a 0.3 0.1' 0.0
6 1.0 0.0a 0.3 ' 0.3 a 0.1 a 0.1'
7 0.6 0.0a 0.1 a 0.2' 0.4 0.3
8 1.0 0.2 ' 0.2a 0.1
a 0.1
a 0.1
a
a Indicates significant decreases (p<0.05) from historical control.
cause of unusually low or high control values.
In general, mean values for parameters tend
to be low at all dose levels when they are
low for controls and high when controls are
high, because of variability which is due to
unexplained causes.
Relationship of Dominant Lethality
to Heritable Effects
If the primary focus of our concern in
mutagenesis is the threat to future genera-
tions, in terms of effects on the gene pool,
then the dominant-lethal test has yet another
limitation when used for safety evaluation.
The test, by definition, measures only death:
death in the preimplantation stage and/or in
the postimplantation stage. The concern is
that there may be ways in which dominant
lethality can be induced without producing
genetic events with potential transmissibil-
ity to live progeny.
It has been pointed out that there is a
genetic disease burden in the population (6).
In order to determine whether agents capa-
ble of increasing this burden exist at the
present time we need systems and approaches
capable of detecting such effects. The
dominant-lethal system measures such a nar-
row spectrum of genetic effects (gross chro-
mosomal aberrations manifested as dead im-
plantations) that it is severely limiting in
the type of information one can glean from
it.
There have been attempts to examine live
progeny for cytogenetic abnormalities in
order to expand the amount of information
that the system provides. To our knowledge,
only one group has been successful with this
technique (7). There is a need for more
information in this area and for additional
approaches which measure genetic effects in
progeny.
REFERENCES
1. Anonymous. FDA reveals testing priorities for
GRAS substances. Food Chem. News 13 (No. 11):
18, (1971).
2. Epstein, S. S., et al. Detection of chemical
mutagens by the dominant lethal assay in the
mouse, Toxicol. Appl. Pharmacol. 23: 288 (1972).
3. Bateman, A. J. The induction of dominant lethal
mutations in rats and mice with triethylenemela-
mine (TEM). Genet. Res. Camb. 1: 381 (1960).
4. Jackson, H. Antifertility Compounds in the Male
and Female. Charles C Thomas, Springfield, Ill.,
1966, pp. 20-23.
5. Epstein, S. S., et al. Mutagenic and antifertility
effects of TEPA and METEPA in mice. Toxicol.
Appl. Pharmacol. 17: 23 (1970).
6. Childs, B. Miller, S. M., and Bearn, A. G. Gene
mutation as a cause of human disease. In:
Mutagenic Effects of Environmental Contami-
nants, H. E. Sutton and M. I. Harris, Eds.,
Academic Press, New York-London, 1972.
7. Datta, P. K., Frigger, H., and Scheiermacher, E.
The effect of chemical mutagens on the mitotic
chromosomes of the mouse, in vivo. In: Chemical
Mutagens in Mammals and Man. F. Vogel and G.
Rohrborn, Eds., Springer Verlag, Berlin-New
York, 1970.
46 Environmental Health Perspectives